Global HIV Vaccine Market Future Outlook
|出版日期||內容資訊||英文 275 Pages
|HIV疫苗的全球市場與未來展望 Global HIV Vaccine Market Future Outlook|
|出版日期: 2015年05月14日||內容資訊: 英文 275 Pages||
本報告提供全球各國HIV (人類免疫缺陷病毒) 疫苗市場趨勢，及開發平台產品的開發情形相關分析、HIV疫苗的特性和作用機制、整體市場結構、趨勢、開發中產品的目前開發情形主要課題、產品單位 (共100種產品) 及各臨床實驗階段的詳細的開發情形、已上市產品 (共42種產品) 銷售情形、今後的市場方向性的資訊，為您概述為以下內容。
Vaccine discovery, designing, research and development science is backed by several decades of knowledge. Every year, new vaccine for treating infectious diseases is entering in the market and their quality along with pharmacological efficacy is increasing. Innovative modalities have been found and market is overcrowded with the number of vaccines for different infectious diseases. In this scenario, absence of HIV vaccines becomes a pertinent question in front of investigators funded by both pharmaceutical companies and medical regulatory authorities. Gravity of the situation could also be understood by the fact that HIV clinical trials have failed to produce pharmacological benefits despite availability of suitable infrastructure. Simultaneously, HIV incidences are escalating tremendously across the globe due to which necessity for this vaccine is becoming more essential. All these facts support the imminent market introduction of HIV vaccines in global market to prevent progression and proliferation of AIDS epidemic.
Clinical trials are being done for across the globe for development of HIV vaccines and these efforts have yielded significant results. Investigators have identified artificial molecules that could mimic the HIV infection as result of which immune system would be activated. Their efficacy has been proved and clinical trials using them have yet to instigate. Several different modalities are also under investigation which may lead to development of relatively high cure rates. Certain receptors are also under investigation which has been found to be involved during initial phase of HIV infection. Immunoglobins may also serve as an ideal candidate due to their involvement in immune system activation. Beside this, several innovative modalities has been proposed for the treatment of HIV and emphasis is being given on the development of prophylactic vaccines. Several lead molecules have been discovered and their pharmacological efficacy is under investigation. In this way, investigators are expected to find some worthy candidate to the development of HIV vaccine.
Recombinant DNA technologies and genetic engineering has been widely used for the development of vaccines for several infectious diseases. These technologies are also being used for the development of HIV vaccines that would be commercialized in global market in coming years. Genetic manipulation of HIV is under consideration to develop a strain which have all molecular signatures but no pathogenicity. This decoy strain will activate the immune system to develop active immunity. Novel modalities include, use of recombinant molecules having higher immune eliciting capabilities. Computerized simulations are also being used for analysis of obscure vaccine candidates having pharmaceutical potential. This technology is expected to decrease the valuable time and precious resources utilized in the screening of proposed candidate. Furthermore, investigators are developing methodologies to find the effect of HIV gene expression on nonpathogenic bacterial/viral vectors.
Pharmaceutical companies have recognized the dearth of effective HIV medications due to which they are investing significant amount on research and development of HIV vaccines. Various candidates are at different stages of clinical trials and they would be introduced in market in coming years. Technology is developing at rapid rates due to which screening of selected candidate is expected to take place at lesser time. In this way, market winding times are expected to decrease due to lesser time in developmental phases. Manufacturing capabilities are highly developed but some tweaking has to be done according to HIV pathogen. Significant development in recombinant DNA technology and genetic engineering is also expected to accelerate the rate of HIV vaccine development. Investigators are also expected to find new modalities that will help in checking the AIDS. In this way, future of HIV vaccines market looks optimistic and it may be commercialized in next 5-10 years.
"Global HIV Vaccine Market Future Outlook" Report Highlights: